Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease

Journal of Immunology

Volumn 180, Issue 4, 2008, Pages 2704-2712

  Palmer, Brent E ^a   Mack, Douglas G ^a   Martin, Allison K ^a   Gillespie, May ^b   Mroz, Margaret M ^b   Maier, Lisa A ^a,b   Fontenot, Andrew P ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM; METHOTREXATE; PREDNISONE; PROGRAMMED DEATH 1 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; EPITOPE; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; BERYLLIOSIS; BLOOD CELL; BLOOD CHEMISTRY; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL DEATH; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LONG TERM EXPOSURE; LUNG ALVEOLITIS; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; METABOLIC REGULATION; OCCUPATIONAL EXPOSURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; UPREGULATION; BIOSYNTHESIS; CELL PROLIFERATION; COMPARATIVE STUDY; GENETICS; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; BERYLLIOSIS; BERYLLIUM; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHRONIC DISEASE; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; UP-REGULATION;

EID: 42149085673     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.4.2704     Document Type: Article

References (42)

1. Amicosante, M., and A. P. Fontenot. 2006. T cell recognition in chronic beryllium disease. Clin. Immunol. 121: 134-143.
2. Fontenot, A. P., and L. A. Maier. 2005. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol. 26: 543-549.
3. + T cells in patients with chronic beryllium disease. J. Clin. Invest. 110: 1473-1482.
4. Tinkle, S. S., L. A. Kittle, B. A. Schumacher, and L. S. Newman. 1997. Beryllium induces IL-2 and IFN-γ in berylliosis. J. Immunol. 158: 518-526.
5. + T cells. J. Clin. Invest. 112: 776-784.
6. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
7. + T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179: 1979-1987.
8. + T cells associated with reversible immune dysfunction. J. Virol. 81: 9249-9258.
9. + T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202.
10. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109: 4671-4678.
11. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11: 3887-3895.
12. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126.
13. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
14. Latchman, Y., C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A. J. Long, J. A. Brown, R. Nunes, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2: 261-268.
15. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
16. Chemnitz, J. M., R. V. Parry, K. E. Nichols, C. H. June, and J. L. Riley. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173: 945-954.
17. Ansari, M. J., A. D. Salama, T. Chitnis, R. N. Smith, H. Yagita, H. Akiba, T. Yamazaki, M. Azuma, H. Iwai, S. J. Khoury, et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198: 63-69.
18. Fife, B. T., I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone. 2006. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203: 2737-2747.
19. + T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol. 30: 1410-1419.
20. Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895.
21. Wan, B., H. Nie, A. Liu, G. Feng, D. He, R. Xu, Q. Zhang, C. Dong, and J. Z. Zhang. 2006. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177: 8844-8850.
22. Jones-Williams, W., and D. Kelland. 1986. New aid for diagnosing chronic beryllium disease (CBD): laser ion mass analysis (LIMA). J. Clin. Pathol. 39: 900-901.
23. Jones-Williams, W., and E. R. Wallach. 1989. Laser microprobe mass spectrometry (LAMMS) analysis of beryllium, sarcoidosis, and other granulomatous diseases. Sarcoidosis 6: 111-117.
24. Sawyer, R. T., J. L. Abraham, E. Daniloff, and L. S. Newman. 2005. Secondary ion mass spectroscopy demonstrates retention of beryllium in chronic beryllium disease granulomas. J. Occup. Environ. Med. 47: 1218-1226.
25. Newman, L. S., K. Kreiss, T. E. King, Jr., S. Seay, and P. A. Campbell. 1989. Pathologic and immunologic alterations in early stages of beryllium disease: reexamination of disease definition and natural history. Am. Rev. Respir. Dis. 139: 1479-1486.
26. Rossman, M. D., J. A. Kern, J. A. Elias, M. R. Cullen, P. E. Epstein, O. P. Preuss, T. N. Markham, and R. P. Daniele. 1988. Proliferative response of bronchoalveolar lymphocytes to beryllium. Ann. Intern. Med. 108: 687-693.
27. Newman, L. S. 1996. Significance of the blood beryllium lymphocyte proliferation test. Environ. Health Perspect. 104: 953S-956S.
28. Mroz, M. M., K. Kreiss, D. C. Lezotte, P. A. Campbell, and L. S. Newman. 1991. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J. Allergy Clin. Immunol. 88: 54-60.
29. Fontenot, A. P., B. L. Kotzin, C. E. Comment, and L. S. Newman. 1998. Expansions of T-cell subsets expressing particular T cell receptor variable regions in chronic beryllium disease. Am. J. Respir. Cell. Mol. Biol. 18: 581-589.
30. Fontenot, A. P., M. T. Falta, B. M. Freed, L. S. Newman, and B. L. Kotzin. 1999. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J. Immunol. 163: 1019-1026.
31. + T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 175: 8415-8423.
32. + T cells in blood determines proliferative response. J. Clin. Invest. 115: 2886-2893.
33. + T cell maturation and function. J. Immunol. 172: 3337-3347.
34. Sallusto, F., and A. Lanzavecchia. 2001. Exploring pathways for memory T cell generation. J. Clin. Invest. 108: 805-806.
35. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
36. + T cell survival in HIV infection. J. Exp. Med. 203: 2281-2292.
37. Bilyk, N., and P. G. Holt. 1993. Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 177: 1773-1777.
38. Holt, P. G., J. Oliver, N. Bilyk, C. McMenamin, P. G. McMenamin, G. Kraal, and T. Thepen. 1993. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J. Exp. Med. 177: 397-407.
39. Strickland, D., U. R. Kees, and P. G. Holt. 1996. Regulation of T-cell activation in the lung: alveolar macrophages induce reversible T-cell anergy in vitro associated with inhibition of interleukin-2 receptor signal transduction. Immunology 87: 250-258.
40. Sauce, D., J. R. Almeida, M. Larsen, L. Haro, B. Autran, G. J. Freeman, and V. Appay. 2007. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 21: 2005-2013.
41. + T cells specific for both persistent and non-persistent viruses display distinct differentiation phenotypes but have similar level of PD-1 expression in healthy Chinese individuals. Clin. Immunol. In press.
42. + T cells in patients with beryllium-induced disease. J. Allergy Clin. Immunol. 115: 1036-1042.